Rezolute (NASDAQ:RZLT) Given New $15.00 Price Target at Citizens Jmp

Rezolute (NASDAQ:RZLT) had its price objective raised by Citizens Jmp from $11.00 to $15.00 in a research note released on Tuesday morning,Benzinga reports. Citizens Jmp currently has a market outperform rating on the stock.

A number of other analysts have also recently weighed in on RZLT. Cantor Fitzgerald raised shares of Rezolute from a “neutral” rating to an “overweight” rating in a report on Monday. Craig Hallum raised shares of Rezolute from a “hold” rating to a “buy” rating and boosted their target price for the company from $4.00 to $7.00 in a research note on Tuesday, September 29th. HC Wainwright upped their target price on shares of Rezolute from $5.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, September 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Rezolute in a research note on Friday, July 17th. Finally, Wall Street Zen cut Rezolute from a “hold” rating to a “sell” rating in a report on Tuesday, June 30th. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $11.22.

Rezolute Price Performance

Shares of RZLT opened at $4.32 on Tuesday. Rezolute has a 12 month low of $1.07 and a 12 month high of $11.46. The stock has a fifty day moving average price of $4.47 and a 200 day moving average price of $4.09. The company has a market cap of $417.83 million, a P/E ratio of -5.68 and a beta of 0.53.

Rezolute (NASDAQ:RZLT) last posted its earnings results on Thursday, September 24th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05). As a group, research analysts anticipate that Rezolute will post -0.6 earnings per share for the current year.

Institutional Investors Weigh In On Rezolute

Institutional investors have recently bought and sold shares of the stock. AlphaCentric Advisors LLC boosted its holdings in shares of Rezolute by 6.2% in the first quarter. AlphaCentric Advisors LLC now owns 71,227 shares of the company’s stock valued at $217,000 after acquiring an additional 4,171 shares in the last quarter. Auxano Advisors LLC bought a new stake in Rezolute during the second quarter worth approximately $52,000. Sequoia Financial Advisors LLC bought a new stake in Rezolute during the second quarter worth approximately $75,000. WINTON GROUP Ltd acquired a new stake in Rezolute in the second quarter worth approximately $88,000. Finally, ADAR1 Capital Management LLC lifted its position in Rezolute by 51.7% in the first quarter. ADAR1 Capital Management LLC now owns 58,679 shares of the company’s stock worth $179,000 after purchasing an additional 20,000 shares during the period. Institutional investors and hedge funds own 82.97% of the company’s stock.

Key Headlines Impacting Rezolute

Here are the key news stories impacting Rezolute this week:

• Positive Sentiment: The FDA recommended a pre-BLA meeting, an important regulatory step that could help Rezolute prepare a potential biologics license application for ersodetug. The agency also reiterated its commitment to addressing the significant unmet need in hyperinsulinism. The meeting does not guarantee approval, but it indicates that discussions toward a possible filing can continue. Rezolute FDA pre-BLA announcement
• Positive Sentiment: Cantor Fitzgerald upgraded RZLT to “Overweight” from “Neutral,” citing the pre-BLA meeting opportunity for ersodetug. Cantor Fitzgerald upgrades Rezolute
• Positive Sentiment: Citizens JMP raised its price target from $11 to $15 and assigned a “Market Outperform” rating, implying substantial upside from the referenced $4.32 share price. Rezolute stock price expected to rise
• Neutral Sentiment: Call-option activity surged, with investors purchasing 4,099 calls—about 618% above average volume—signaling speculative bullish interest but not a fundamental business change.
• Negative Sentiment: Rezolute still faces clinical and regulatory risk following a Phase 3 trial miss. A pre-BLA meeting is not an approval or a guarantee that the FDA will accept a future BLA, making additional data and regulatory discussions critical.

About Rezolute

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. The company’s research is centered on conditions involving abnormal insulin signaling and glucose regulation, including rare disorders and complications associated with diabetes.

Rezolute’s lead investigational product is RZ358, a human monoclonal antibody designed to reduce the effects of excessive insulin activity. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin and causes potentially dangerous episodes of low blood sugar.